Cumberland Pharmaceuticals (CPIX) Cash from Financing Activities (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) reported Cash from Financing Activities of -$763300.0 for Q1 2026, up 86.19% on a YoY basis from -$409963.4 in Q1 2025, and down 11.96% sequentially from -$681738.0 in Q4 2025.
Cumberland Pharmaceuticals (CPIX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals (CPIX) has 17 years of Cash from Financing Activities data on file, last reported at -$763300.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 86.19% year-over-year to -$763300.0; the trailing twelve-month figure through Mar 2026 stood at -$2.0 million (up 74.42% YoY), and the FY2025 full-year result was -$6.7 million, down 3525.79% from the prior year.
- Cash from Financing Activities eased to -$763300.0 in Q1 2026, from -$681738.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $3.9 million in Q1 2022 to a low of -$5.5 million in Q1 2025.
- A 5-year average of -$988127.6 and a median of -$882596.0 in 2023 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 401.86% in 2022, while the deepest fall reached 619.86% in 2022.
- Tracing CPIX's Cash from Financing Activities over 5 years: stood at -$2.8 million in 2022, then soared by 46.52% to -$1.5 million in 2023, then rose by 7.31% to -$1.4 million in 2024, then jumped by 50.54% to -$681738.0 in 2025, then decreased by 11.96% to -$763300.0 in 2026.
- Business Quant data shows CPIX's Cash from Financing Activities at -$763300.0 in Q1 2026, -$681738.0 in Q4 2025, and -$386879.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.04 Bn | 20.89 Bn | 648.10 Mn | -1.48 Bn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.40 Bn | 18.60 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.49 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.17 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Cumberland Pharmaceuticals | 101.73 Mn | 90.72 Mn | 7.20 Mn | -763,300.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -763,300.00 |
| Mar 31, 2026 | -763,300.00 |
| Dec 31, 2025 | -681,738.00 |
| Dec 31, 2025 | -681,738.00 |
| Sep 30, 2025 | -386,879.00 |
| Sep 30, 2025 | -386,879.00 |
| Jun 30, 2025 | -150,797.00 |
| Jun 30, 2025 | -150,797.00 |
| Mar 31, 2025 | -5.53 Mn |
| Mar 31, 2025 | -5.53 Mn |
| Dec 31, 2024 | -1.38 Mn |
| Dec 31, 2024 | -1.38 Mn |
| Sep 30, 2024 | -536,836.00 |
| Sep 30, 2024 | -536,836.00 |
| Jun 30, 2024 | -309,575.00 |
| Jun 30, 2024 | -309,575.00 |
| Mar 31, 2024 | 2.42 Mn |
| Mar 31, 2024 | 2.42 Mn |
| Dec 31, 2023 | -1.49 Mn |
| Dec 31, 2023 | -1.49 Mn |